4.6 Article

T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4

期刊

JOURNAL OF BIOLOGICAL CHEMISTRY
卷 295, 期 33, 页码 11486-11494

出版社

ELSEVIER
DOI: 10.1074/jbc.RA120.014016

关键词

cancer-associated antigen; melanoma antigen-A4 (MAGE-A4); immuno-oncology; crystal structure; peptide-human leukocyte antigen (pHLA); surface plasmon resonance (SPR); T cell receptor (TCR); adaptive immunity; antigen recognition; cancer therapy; immunotherapy; antigen presentation; antigen recognition; cancer-associated antigen; MAGE-A4; peptide-human leukocyte antigen; T cell receptor

向作者/读者索取更多资源

T cell-mediated immunity is governed primarily by T cell receptor (TCR) recognition of peptide-human leukocyte antigen (pHLA) complexes and is essential for immunosurveillance and disease control. This interaction is generally stabilized by interactions between the HLA surface and TCR germline-encoded complementarity-determining region (CDR) loops 1 and 2, whereas peptide selectivity is guided by direct interactions with the TCR CDR3 loops. Here, we solved the structure of a newly identified TCR in complex with a clinically relevant peptide derived from the cancer testis antigen melanoma antigen-A4 (MAGE-A4). The TCR bound pHLA in a position shifted toward the peptide's N terminus. This enabled the TCR to achieve peptide selectivity via an indirect mechanism, whereby the TCR sensed the first residue of the peptide through HLA residue Trp-167, which acted as a tunable gateway. Amino acid substitutions at peptide position 1 predicted to alter the HLA Trp-167 side-chain conformation abrogated TCR binding, indicating that this indirect binding mechanism is essential for peptide recognition. These findings extend our understanding of the molecular rules that underpin antigen recognition by TCRs and have important implications for the development of TCR-based therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据